

Erratum to: “The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients”

Shohei Mizuno,¹ Luuk Gras,² Laurien GA Baaij,² Linda Koster,² Anita D’Souza,³ Parameswaran N. Hari,⁴ Noel Estrada-Merly,⁵ Wael Saber,⁶ Andrew J. Cowan,⁷ Minako Iida,¹ Shinichiro Okamoto,⁸ Hiroyuki Takamatsu,⁹ Koji Kawamura,¹⁰ Yoshihisa Kodera,¹ Nada Hamad,¹¹ Bor-Sheng Ko,¹² Christopher Liam,¹³ Kim Wah Ho,¹⁴ Ai Sim Goh,¹⁵ Tan Sui Keat,¹⁵ Alaa M. Elhaddad,¹⁶ Ali Bazarbachi,¹⁷ Brig Qamar Un N. Chaudhry,¹⁸ Rozan Alfar,¹⁹ Mohamed Amine Bekadja,²⁰ Malek Benakli,²¹ Cristobal Augusto Frutos Ortiz,²² Eloisa Riva,²³ Estelle Verburch,²⁴ Sebastian Galeano,²⁵ Francisca Bass,²⁶ Hira Mian,²⁷ Arleigh McCurdy,²⁸ Feng Rong Wang,²⁹ Daniel Neumann,³⁰ Mickey Boon Chai Koh,³¹ John A. Snowden,³² Stefan Schönland,³³ Donal P. McLornan,³⁴ Patrick J Hayden,³⁵ Anna Maria Sureda Balari,³⁶ Hildegard T. Greinix,³⁷ Mahmoud Aljurf,³⁸ Yoshiko Atsuta,^{1,39} Liesbeth C. de Wreede,⁴⁰ Damiano Rondelli,⁴¹ Dietger W. Niederwieser,^{1,42,43#} and Laurent Garderet^{44#} on behalf of the Worldwide Network of Blood and Marrow Transplantation (WBMT)

¹Aichi Medical University School of Medicine, Nagakute, Japan; ²EBMT Leiden Study Unit, Leiden, the Netherlands; ³Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; ⁴Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; ⁵BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; ⁶CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN, USA; ⁷Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; ⁸Keio University School of Medicine, Tokyo, Japan; ⁹Kanazawa University, Kanazawa, Japan; ¹⁰Tottori University Hospital, Yonago, Japan; ¹¹Hematology Department, The Kinghorn Cancer Center, St Vincent’s Hospital, Darlinghurst, New South Wales, Australia; ¹²National Taiwan University Hospital, Taipei, Taiwan; ¹³Hospital Sultanah Aminah, Johor Bahru, Malaysia; ¹⁴Hospital Ampang, Ampang, Malaysia; ¹⁵Hospital Pulau Pinang, Pinang, Malaysia; ¹⁶Cairo University, Cairo, Egypt; ¹⁷Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon; ¹⁸Armed Forces Institute of Transplantation, Rawalpindi, Pakistan; ¹⁹King Hussein Cancer Center, Amman, Jordan; ²⁰Établissement Hospitalier Universitaire 1 et Novembre, Ahmed Benbella 1 University, Oran, Algeria; ²¹Pierre and Marie Curie Center, Algiers, Algeria; ²²Instituto de Prevision Social, Asuncion, Paraguay; ²³Clinical Hospital Dr. Manuel Quintela De Clinicas, Montevideo, Uruguay; ²⁴Groote Schuur Hospital, Cape Town, South Africa; ²⁵British Hospital, Montevideo, Uruguay; ²⁶Intensive Hematology Unit, Hospital Del Salvador, Santiago, Chile; ²⁷McMaster University, Hamilton, Ontario, Canada; ²⁸The Ottawa Hospital, Ottawa, Ontario, Canada; ²⁹Peking University, Peking, China; ³⁰IMISE, University of Leipzig, Leipzig, Germany; ³¹City St Georges, University of London and St Georges University Hospitals, London, UK; ³²Department of Hematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; ³³University Hospital Heidelberg, Heidelberg, Germany; ³⁴University College London Hospitals NHS Trust, London, UK; ³⁵Department of Medicine, Trinity College Dublin, St. James’s Hospital, Dublin, Ireland; ³⁶Universitat de Barcelona, Barcelona, Spain; ³⁷Medical University Graz, Graz, Austria; ³⁸King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; ³⁹Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan; ⁴⁰Department of Biomedical Data Sciences, Leiden University Medical Center, the Netherlands; ⁴¹Division of Hematology/Oncology, University of Illinois at Chicago -UI Health, Chicago, IL, USA; ⁴²University of Leipzig, Leipzig, Germany; ⁴³Penn Medicine, Philadelphia, PA, USA and ⁴⁴Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpêtrière, Service d’Hématologie, Paris, France

[#]DWN and LG contributed equally as senior authors.

Correspondence: S. Mizuno
shohei@aichi-med-u.ac.jp

Received: March 12, 2026.
Accepted: March 12, 2026.

<https://doi.org/10.3324/haematol.2026.289429>

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license



The published article¹ by mistake failed to list the author Liesbeth C. de Wreede, who as a statistician made essential contributions to the work by evaluating the age-dependent excess mortality in the patient population. She also helped to design the study, analyzed the data in comparison to the age-related mortality of a normal population and wrote/corrected the manuscript. Her name has been added to the list of authors and her affiliation is now correctly listed as: ⁴⁰Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands. Her name has also been added to the Contributions and the correct Contributions are therefore as follows: SM, LGa, LGr, MA, YA, LCdW, and DN designed the study. LK, LB, AD, NEM, PH, WS, AC, MI, SO, HT, SM, KK, YK, NH, BSK, CL, KWH, ASG, SKT, AME, AB, QNC, RA, MAB, MB, CAFO, ER, SG, FB, HM, AMcC, FRW, MK, JS, SS, DMcL, PH, AS, and HG enrolled patients. SM, LGa, LGr, DNe, NH, MA, YA, LCdW, and DN analyzed the data. SM, LGa, LGr, DNe, NH, MA, EV, YA, GS, LCdW, and DN wrote the manuscript. Furthermore the correct Disclosures are as follows:

References

1. Mizuno S, Gras L, Baajj LGA, et al. The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients. *Haematologica*. 2026;111(1):286-299.

SM received research funding from Hayashikane Sangyo and lecture fees from Johnson & Johnson. AD’S reports clinical trial funding to institution from Abbvie, Alexion, Prothena, Janssen, Novartis, and Regeneron; discloses IRC, data monitoring committee, or steering committee role with Abbvie, BMS, Janssen, and Prothena; further discloses an advisory nboard role with Abbvie, BMS, Janssen, Prothena, and Pfizer. MI received research funding from AIR WATER Inc.. HT received honorarium from Janssen, Ono, Sanofi, and Bristol-Myers Squibb; and discloses consultancy fees from Adaptive Biotechnologies. KK discloses honoraria from Sanofi. JAS discloses consulting fees from Medac, Jazz, MSD, and Vertex. YA received lecture fee/honorarium from Otsuka Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co. Ltd., Novartis Pharma K.K., Meiji Seika Pharma Co. Ltd., and Janssen Pharmaceutical K.K.; and discloses consultant fees from JCR Pharmaceuticals Co., Ltd. LG received consultancy fees from Janssen, Bristol-Myers Squibb, Sanofi, Pfizer, and GSK. All other authors including LCdW have no conflicts of interest to disclose.